Topic: infectious disease
Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.
Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.
Pardis Sabeti, co-founder, Sherlock Biosciences
Merck's antibiotic Recarbrio won its first FDA nod in July. Now, thanks to new trial results in severe pneumonia, it's eyeing another approval.
Gilead Sciences' new HIV funding effort looks to grant an initial $2 million to groups that help transgender people.
Merck won a label expansion for Zerbaxa, an antibiotic the company picked up in its 2014 buyout of Cubist Pharmaceuticals.
Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.
With HIV rates in the U.S. holding steady, health officials are looking to drugmakers to help drive down infections. Now, Gilead is ready to chip in.
The U.S. is seeing a spike in measles cases, but Merck, the sole producer of the measles vaccine for the U.S., says it has production in hand.
With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.